Kedudukan dalam Saham
#22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Harga Saham
$0.04959193
Disegerakkan terakhir: 2025-03-17
Perubahan (1 hari)
13.49%
Perubahan (1 tahun)
0.00%
Perdagangan Abliva AB (publ) (ABLI)
Harga ABLI dengan permodalan pasaran b
Modal pasaran bagi Abliva AB (publ)(ABLI)
Modal Pasaran: $79.94M
Sehingga August 2026, Abliva AB (publ) mempunyai modal pasaran sebanyak $79.94M. Ini menjadikan Abliva AB (publ) syarikat ke-22998th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Abliva AB (publ) dari 2008 hingga 2026
ABLI berbanding dengan 5 teratas yang paling popular stocks
| Harga ABLI |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.211T
|
+6,519,334.37%
|
|
|
|
|
$4.547T
|
+5,687,889.61%
|
|
|
|
|
$4.162T
|
+5,207,166.93%
|
|
|
|
|
$3.593T
|
+4,494,489.39%
|
|
|
|
|
$2.793T
|
+3,493,767.13%
|
